# A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan

> **NCT06596642** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 61 (actual)

## Conditions studied

- β-Thalassemia Major

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT06596642
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-21
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-12-17
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06596642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06596642, "A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06596642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*